Drug intelligence / Profile preview

IBgard

Development stage
Unknown
Lead developer
IM HealthScience
Modality
Small Molecules
Administration
Oral
01

Overview

IBgard is an over-the-counter medical food and dietary supplement specifically formulated for the dietary management of irritable bowel syndrome (IBS). Developed by IM HealthScience (now a part of Nestlé Health Science), it contains ultra-purified peppermint oil (Ultramen®) as its active ingredient, with L-menthol being the primary component. The product utilizes a patented Site-Specific Targeting (SST) technology, which consists of triple-coated, sustained-release microspheres designed to bypass the stomach and release the peppermint oil directly in the small intestine. Its mechanism of action is multifaceted, primarily involving calcium channel antagonism in gastrointestinal smooth muscle to provide antispasmodic effects. It also exhibits anti-inflammatory, carminative, kappa opioid agonist, and serotonergic antagonist properties. IBgard is clinically indicated to manage a combination of IBS symptoms, including abdominal pain, bloating, cramping, and urgency, with an onset of action reported in as little as 24 hours.

Brand names
IBgard
Other names
Ultramen Peppermint Oil
02

Targets

CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on IBgard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBgard.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call